Le premier patient a été traité dans la phase de randomisation de l'essai de phase 3 DESTINY-Ovarian01, évaluant l'ENHERTU® (trastuzumab déruxtecan) en association avec le bévacizumab, comparé à la ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback